Evidence map›Paper›PMID 21172079›Full record

Trial reportBreast cancer research : BCR2010

Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.

James N Ingle

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Breast cancer research : BCR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

James N IngleMayo Clinic, Rochester, MN 55905, USA. ingle.james@mayo.edu

Funding

The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
PHARMACOGENETICS OF PHASE II DRUG METABOLIZING ENZYMESU01GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2000 to 2009
$15.7M
NCIC Foreign AccrualsU10CA077202 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI EISENHAUER, ELIZABETH · 1998 to 2013
$14.6M
The Johns Hopkins Folding MeetingR13GM063173 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI LATTMAN, EATON E · 2001 to 2001
$5k
NCI NIH HHS P50 CA116201NCI NIH HHS P50CA116201NCI NIH HHS U10CA77202NIGMS NIH HHS U01GM61388NIGMS NIH HHS U01GM63173
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Polymorphism, Single NucleotideAnastrozoleAndrostadienesAntineoplastic AgentsAromatase InhibitorsBreast NeoplasmsCase-Control StudiesFemaleGene ExpressionGenome-Wide Association StudyHumansInterleukin-17Linkage DisequilibriumMusculoskeletal DiseasesNitrilesPharmacogeneticsAnastrozoleAndrostadienesAntineoplastic AgentsAromatase InhibitorsexemestaneInterleukin-17NitrilesTriazoles

Identifiers

PMID21172079
PMCPMC3005737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.